Journal of Clinical Lipidology
Volume 3, Issue 4 , Pages 275-280 , August 2009

Effects of lifestyle counseling and combination lipid-modifying therapy on lipoprotein-associated phospholipase A2 mass concentration

  • Kota J. Reddy, MD

      Affiliations

    • Reddy Cardiac Wellness, Cardiology, 3519 Town Center BLVD, Suite A, Sugar Land, TX, USA
    • ,
  • Manmeet Singh, MD

      Affiliations

    • Reddy Cardiac Wellness, Cardiology, 3519 Town Center BLVD, Suite A, Sugar Land, TX, USA
    • Corresponding Author InformationCorresponding author.
    • ,
  • Richard R. Batsell, PhD

      Affiliations

    • Rice University, Houston, TX, USA
    • ,
  • Joey R. Bangit, MD

      Affiliations

    • Reddy Cardiac Wellness, Cardiology, 3519 Town Center BLVD, Suite A, Sugar Land, TX, USA
    • ,
  • Rekha A. Miraskar, MD

      Affiliations

    • Reddy Cardiac Wellness, Cardiology, 3519 Town Center BLVD, Suite A, Sugar Land, TX, USA
    • ,
  • Misbah S. Zaheer, MD

      Affiliations

    • Reddy Cardiac Wellness, Cardiology, 3519 Town Center BLVD, Suite A, Sugar Land, TX, USA
    • ,
  • Carol Cockerham, MS

      Affiliations

    • Reddy Cardiac Wellness, Cardiology, 3519 Town Center BLVD, Suite A, Sugar Land, TX, USA
    • ,
  • Michael Wegner, PhD

      Affiliations

    • diaDexus Inc, San Francisco, CA, USA

Received 18 March 2009 ,Accepted 26 June 2009.

References 

  1. Miniño AM, Heron MP, Murphy SL, Kochanek KD. Deaths: final data for 2004. Natl Vital Stat Rep. 2007;55:7
  2. Kesteloot H, Sans S, Kromhout D. Dynamics of cardiovascular and all-cause mortality in Western and Eastern Europe between 1970 and 2000. Eur Heart J. 2006;27:107–113
  3. Thom T, Haase N, Rosamond W, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85–e151
  4. Rosamond W, Flegal K, Furie K, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25–e146
  5. National cholesterol education program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Third report of national cholesterol education program expert panel on Detection, Evaluation and treatment of high blood cholesterol in adults. Circulation. 2002;106:3143–3421II-30−II-31
  6. Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;290:898–904
  7. Garza CA, Montori VM, McConnell JP, Somers VK, Kullo IJ, Lopez-Jimenz F. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systemic review. Mayo Clin Proc. 2007;82:159–165
  8. Falk E, Shah PK, Fuster V. Coronary plaque disruption (review). Circulation. 1995;92:657–671
  9. Häkkinen T, Luoma JS, Hiltunen MO, et al. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 1999;19:2909–2917
  10. Kolodgie FD, Burke AP, Taye A. Lipoprotein -associated phospholipase a2 is highly expressed in macrophages of coronary lesions prone to rupture. Presented at the Annual scientific sessions of American Heart Association, 11 Nov 2004, New Orleans LO, USA.
  11. MacPhee CH, Moores KE, Boyd HF, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J. 1999;338:479–487
  12. Quinn MT, Parthasarathy S, Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci U S A. 1988;85:2805–2809
  13. Elisaf M, Tselepis AD. Effect of hypolipidemic drugs on lipoprotein associated platelet activating factor acetlyhydrolase. Implication for atherosclerosis. Biochem Pharmacol. 2003;66:2069–2073
  14. Tambaki AP, Rizos E, Tsimihodimos V, Tselepis AD, Elisaf M. Effect of antihypertensive and hypolipidemic drugs on plasma and HDL-associated PAF-acetylhydrolase activity. J Cardiovasc Pharmacol Ther. 2004;9:91–95
  15. Tsimihodimos V, Karabina SA, Tambaki AP, et al. Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler Thromb Vasc Biol. 2002;22:306–311
  16. Schaefer EJ, McNamara JR, Asztalos BF, et al. Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects. Am J Cardiol. 2005;95:1025–1032
  17. Kudolo GB, Bressler P, DeFronzo RA. Plasma PAF acetylhydrolase in non-insulin dependent diabetes mellitus and obesity: effect of hyperinsulinemia and lovastatin treatment. J Lipid Mediat Cell Signal. 1997;17:97–113
  18. Zhang B, Fan P, Shimoji E, et al. Modulating effects of cholesterol feeding and simvastatin treatment on platelet-activating factor acetylhydrolase activity and lysophosphatidylcholine concentration. Atherosclerosis. 2006;186:291–301
  19. Winkler K, Abletshauser C, Friedrich I, Hoffmann MM, Wieland H, Marz W. Fluvastatin slow release lowers platelet activating factor acetyl hydrolase activity: a placebo controlled trial in patients with Type 2 diabetes. J Clin Endocrinol Metab. 2004;89:1153–1159
  20. Caslake MJ, Packard CJ, Suckling KE, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis. 2000;150:413–419
  21. Saougos VG, Tambaki AP, Kalogirou M, et al. Differentials effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arteriosclerosis Thromb Vasc Biol. 2007;27:2236–2243
  22. Kuvin JT, Dave DM, Sliney KA, et al. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol. 2006;98:743–745
  23. Gaubatz JW, Gillard BK, Massey JB, et al. Dynamics of dense electronegative low density lipoproteins and their preferential association with lipoprotein phospholipase A(2). J Lipid Res. 2007;48:348–357
  24. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the investigation of treatment effects of reducing cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110:3512–3517
  25. Zhao XQ, Yuan C, Hatsukami TS, et al. Effects of prolonged intensive lipid –lowering therapy on the characterstics of carotid atherosclerosis plaques in vivo by MRI: a case–control study. Arterioscler Thromb Vasc Biol. 2001;21:1623–1629
  26. Albert MA, Glynn RJ, Wolfert RL, Ridker PM. The effect of statin therapy on lipoprotein-associated phospholipase A2 levels. Atherosclerosis. 2005;182:193–198
  27. Muhulestein JB, May HT, Jensen JR, et al. The reduction of inflammatory biomarkers by statin, fibrate and combination therapy among diabetic patients with mixed dyslipidemia. J Am Coll Cardiol. 2006;48:396–401
  28. Schaefer EJ, McNamara JR, Asztalos BF, et al. Effects of atrovastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein associated phospholipase A2 in patients with coronary heart disease versus control subjects. Am J Cardiol. 2005;95:1025–1032
  29. Zhang B, Fan P, Shimoji E, et al. Modulating effects of cholesterol feeding and simvastatin treatment on platelet-activating factor acetylhydrolase activity and lysophosphatidylcholine concentration. Atherosclerosis. 2006;186:291–301
  30. Shalwitz RA, Maki KV, Doyle RT, Ballantyne CM. Lipoprotein subfraction responses differentially predict changes in lipoprotein-associated phospholipase A2 during prescription omega-3 therapy. Arteriosclerosis, Thrombosis, and Vascular Biology Annual Conference. 2007;27:e93–e94
  31. O'Donoghue M, Morrow DA, Sabatine MS, et al. Lp-PlA2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE-IT-TIMI 22. Circulation. 2006;113:1745–1752
  32. Winkler K, Abletshauser C, Friedrich I, Hoffman NM. Wieland H, März W. Fluvstatin, slow- release lowers platlet-activating factors acetyl hydrolase activity; a placebo controlled trial in patients with type 2 diabetes. J Clin Endocrinol Metab. 2005;89:1153–1159
  33. Davidson MH, Stein EA, Bays HE, et al. COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther. 2007;29:1354–1367
  34. Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr. 2002;21:495–505
  35. Engler MB. Vascular effects of omega-3 fatty acids: possible therapeutic mechanisms in cardiovascular disease. J Cardiovasc Nurs. 1994;8:53–67
  36. Babcock TA, Dekoj T, Espat NJ. Experimental studies defining omega-3 fatty acid antiinflammatory mechanisms and abrogation of tumor-related syndromes. Nutr Clin Pract. 2005;20:62–74
  37. Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin. 2006;22:2243–2250

PII: S1933-2874(09)00273-6

doi: 10.1016/j.jacl.2009.06.004

Journal of Clinical Lipidology
Volume 3, Issue 4 , Pages 275-280 , August 2009

Article Tools

* Image Usage & Resolution